Take charge of your studies with clear pricing and next-level tools
Provide speed and savings with a single platform that scales to support your client portfolio from beginning to end. Book a meeting to learn more and demo our exclusive pricing tool.
Business-winning
tools at your fingertips
- Leverage GenAI and automation to build higher quality studies faster and more efficiently, while de-risking data collection
- Generate study specific quotes in 30-seconds with our self-serve pricing calculator
- Walk into any kickoff or bid defense meeting with a pre-built digital study, ready for instant feedback and real-time updates
Flexible service tiers built for how you work
Managed Service
- End-to-end study builds by Medable
- Dedicated expertise from instrument and translation management to device provisioning
- Full enablement training, change management, and help desk support
Hybrid
- Unlimited sales/POC workspace for sponsor demos and meetings
- Collaborative Study Support
- Flexible Service Access
- Collaborative Training Approach
Self Service
- Fully enabled to manage builds independently
- Flexible add-on partner support from instrument and translation management to device provisioning
- Complete training, change management, and help desk support
- Priority roadmap input and early access for new AI capabilities and tech releases
Build smarter. Win more.
Create sponsor confidence with every milestone hit
Reach key milestones weeks ahead of schedule, from FPI to translations to build time, while boosting site and patient adherence rates.
Build and scale faster using Medable Studio with AI
Build 35x faster with unlimited workspaces, demo support for customer and bid defense meetings, and a portfolio content library that makes reuse and scale effortless.
Unlock more with our partner incentives
Get access to pricing tools, governance meetings, and sales workspaces-- everything you need to make faster, more informed decisions and scale efficiently.
Trusted By
The latest from Medable
Recapping DIA 2025
The 2025 Drug Information Association (DIA) Global Annual Meeting, held in Washington D.C., is beginning to wind down. As always, the conference has left a clear vision for the future of clinical trials. one defined by groundbreaking innovation, unprecedented global collaboration, and a profound commitment to patient well-being. This year's conference underscored key themes that are shaping the landscape of medical product development, with Artificial Intelligence (AI) and Real-World Data (RWD) taking center stage.
Drive scale with total control: Medable's new CRO partner program
What does it mean to do the heavy lifting?
In clinical research, it means assisting with research and development of new drugs alongside pharmaceutical and biotechnology companies, helping them complete the routine work that turns the gears to make new medicines.
Within pharma, contract research organizations (CROs) are indispensable partners in the advancement of clinical research who manage the complexities of clinical trials from protocol design to regulatory closeout, handling tasks like trial design, patient recruitment, data management, and regulatory submissions.
As a result, CROs have become indispensable partners in the advancement of clinical research who significantly contribute to our industry’s development of groundbreaking treatments, and human health.
However, the weights and the lifting methods have been changing. As Boston Consulting Group noted in their 2024 Nature article, clinical trials are becoming more complex. As a result, CROs face increasing pressure to deliver more with less.
Recognizing their importance in our mission and vision, Medable is excited to announce the launch of our comprehensive CRO partner program, designed to be a game-changing engine for growth and control in the clinical research industry.
.jpg)
Medable perspective: Three points on FDA eCOA guidance
At the beginning of April 2023, the FDA published a draft of the fourth in a series of Guidance Documents entitled “Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments (COA) Into Endpoints For Regulatory Decision-Making”. Once finalized these four documents will be combined and will replace the 2009 Guidance, “Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims”. Part 3, which was released in draft in June 2022, provides advice around the development and validation of new COA (including the modification of existing COA).